Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Zantac 150 — ZANTAC 150
Application NDA018703 (NDA)
Zantac 150 — ZANTAC
Application NDA019090 (NDA)
Unisom — UNISOM
Application NDA019440 (NDA)
Unisom — UNISOM
Application NDA019440 (NDA)
Zantac 150 — ZANTAC
Application NDA019675 (NDA)
Zantac 150 — ZANTAC IN PLASTIC CONTAINER
Application NDA019593 (NDA)
Zantac 150 — ZANTAC 150
Application NDA020251 (NDA)
Zantac 150 — ZANTAC 150
Application NDA020095 (NDA)
Zantac 150 — ZANTAC 75
Application NDA020520 (NDA)
Allegra — ALLEGRA
Application NDA020625 (NDA)
Zantac 150 — ZANTAC 75
Application NDA020745 (NDA)
Zantac 150 — ZANTAC 150
Application NDA021698 (NDA)
Allegra — ALLEGRA
Application NDA021963 (NDA)
Xyzal — XYZAL
Application NDA022064 (NDA)
Xyzal — XYZAL
Application NDA022157 (NDA)
Allegra — ALLEGRA ALLERGY
Application NDA020872 (NDA)
Allegra — CHILDREN'S ALLEGRA ALLERGY
Application NDA201373 (NDA)
Allegra — CHILDREN'S ALLEGRA ALLERGY
Application NDA021909 (NDA)
Xyzal — XYZAL ALLERGY 24HR
Application NDA209090 (NDA)
Xyzal — XYZAL ALLERGY 24HR
Application NDA209089 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)